

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional) **D2973**Application Number **09/904,753**Applicant **R b r t T. Ly ns**Filing Date **07/13/2001**Group Art Unit **1615****U. S. PATENT DOCUMENTS**

EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	RULING DATE IF APPROPRIATE
<i>LM</i>	4,525,346	06-25-1985	Stark	424	80	09-29-1983
	5,171,526	12-15-1992	Wong et al.	422	28	01-05-1990
	5,200,453	04-06-1993	Janssen	514	399	09-17-1990
	5,830,508	11-03-1998	MacKeen	424	602	01-21-1997

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>LM</i> <b>WO 96/25183</b>	<b>22.08.96</b>	<b>PCT</b>			YES NO
					X

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

- |           |    |   |
|-----------|----|---|
| <i>LM</i> | 1  | Maria Bishop, "DG Dispatch-ACR: Topical Cyclosporin A Restores Clear Vision To Sjogren's Syndrome Patients", Doctor's Guide Global Edition, <a href="http://www.pslgroup.com/dg/le96aa.htm">www.pslgroup.com/dg/le96aa.htm</a> , November 3, 2000.            |
|           | 2  | J.H. Lee et al., "High-Level Expression of Antimicrobial Peptide Mediated by a Fusion Partner Reinforcing Formation of Inclusion Bodies", Biochemical and Biophysical Research Communications 277, 575-580, (2000)  |
|           | 3  | Stevenson D., MD et al., "Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate to Severe Dry Eye Disease", Eye News Late 2000-Richmond Eye Associates from Ophthalmology 5/2000; 107:967-974  |
|           | 4  | Gao J, et al., Abstract of "The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy", Department of Biological Science, Allergan, Inc. Cornea 1998 Nov; 17(6): 654-63                     |
|           | 5  | Andrew Acheampong et al., "Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs", Current Eye Research 1999, Vol. 18, No. 2, pp. 91-103   |
|           | 6  | Sall K, et al., Abstract of "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. ScA Phase 3 Study Group.", Ophthalmology 2000 Apr;107(4): 631-9                        |
|           | 7  | Stevenson D., Abstract of "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.", Ophthalmology 2000 May; 107(5):967-74. |
|           | 8  | Katsumi Matsuzaki, "Why and how are peptide-lipide interactions utilized for self-defence? Magainins and tachyplesins as archetypes", Biochimica et Biophysica Acta 1462 (1999) 1-10  |
|           | 9  | David Andreu, "Animal Antimicrobial Peptides: An Overview", Biopolymers (Peptide Science), Vol. 47, 415-433 (1998)  |
|           | 10 | Katsumi Matsuzaki, "Magainins as paradigm for the mode of action of pore forming polypeptides", Biochimica et Biophysica Acta 1376 (1998) 391-400   |
|           | 11 | W. Lee Maloy et al., "Structure-Activity Studies on Magainins and Other Host Defense Peptides", Biopolymers (Peptide Science), Vol. 37, 105-122 (1995)  |
| <i>LM</i> | 12 | Michael Zasloff et al., "Antimicrobial activity of synthetic magainin peptides and several analogues", Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 910-913, February 1988, Microbiology  |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to the applicant.